Get the Stockscreener App
3.41
3.67%
-0.13
After Hours:
3.40
-0.01
-0.29%
Perspective Therapeutics Inc Stock (CATX) Latest News
Its Stock Has Paid Off Big Time For Perspective Therapeutics Inc - SETE News
Perspective Therapeutics (NYSE:CATX) Upgraded by Cantor Fitzgerald to "Strong-Buy" Rating - MarketBeat
CATX overperforms with a 1.52 increase in share price - US Post News
ForexTV | Small Business Resources - ForexTV.com
Perspective Therapeutics to Participate in Upcoming February Investor Conferences - The Manila Times
Precision Oncology Pioneer Perspective Therapeutics Takes Center Stage at Oppenheimer and B. Riley Conferences - StockTitan
Analysts review Perspective Therapeutics Inc’s rating - Knox Daily
Achilles Therapeutics Plc ADR Inc. (ACHL) Price Performance: A Technical Analysis Perspective - The InvestChronicle
Essential Properties Realty Trust Inc [EPRT] Insider Activity: An Update for Investors - Knox Daily
JPMorgan Chase & Co. Has $333,000 Stake in Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World
Lucid raises Perspective Therapeutics stock target to $20 By Investing.com - Investing.com Australia
Lucid raises Perspective Therapeutics stock target to $20 - Investing.com India
Wedbush Reaffirms Outperform Rating for Perspective Therapeutics (NYSE:CATX) - Defense World
Perspective Therapeutics (NYSE:CATX) Receives "Outperform" Rating from Wedbush - MarketBeat
Perspective Therapeutics Touts Encouraging Updated Data From Gastrointestinal Cancer Trial, Stock Soars - AOL
Perspective Therapeutics, Inc. Continues to Pursue Dose Escalation of [212Pb) Vmt-A-Net in Its Ongoing Phase 1/2A Clinical Trial Based on Updated Interim Data Presented At the 2025 Asco Gastrointestinal Cancers Symposium - Marketscreener.com
Perspective Therapeutics Continues to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Updated Interim Data Presented at the 2025 ASCO Gastrointestinal Cancers Symposium - The Manila Times
Perspective's Cancer Drug Shows Promising Results in Phase 1/2a Trial, Zero Toxicity Issues - StockTitan
Cantor Fitzgerald Forecasts CATX FY2025 Earnings - Defense World
Brokers Offer Predictions for CATX FY2025 Earnings - MarketBeat
Perspective Therapeutics to Discuss Data on [212Pb]VMT-α-NET to be Presented at the ASCO Gastrointestinal Cancers Symposium on January 24, 2025 - The Manila Times
Axsome Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on February 18 - The Manila Times
Nuclear Medicine Market Size & Global Growth Report [2032] - Fortune Business Insights
Perspective Therapeutics, Inc. (NYSE:CATX) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
Perspective Therapeutics, Inc. (NYSE:CATX) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Financial Survey: Beyond Air (NASDAQ:XAIR) versus Perspective Therapeutics (NYSE:CATX) - Defense World
Perspective Therapeutics’ (CATX) “Outperform” Rating Reiterated at Royal Bank of Canada - Defense World
Perspective Therapeutics' (CATX) "Outperform" Rating Reiterated at Royal Bank of Canada - MarketBeat
Perspective Therapeutics provides business updates, strategic priorities - Yahoo Finance
Perspective Therapeutics (NYSE:CATX) Receives Outperform Rating from Wedbush - Defense World
Perspective Therapeutics Provides Business Updates and Strategic Priorities Ahead of Presentation at 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Perspective Therapeutics Advances Cancer Pipeline with $227.8M Cash Runway Through 2026 - StockTitan
Barclays PLC Has $1.52 Million Stock Position in Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World
Pre-market Movers: AVGR, TIVC, ATNF, SLGL... - RTTNews
Neumora Therapeutics Inc (NMRA): A New Perspective - Stocks Register
Perspective Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Perspective Therapeutics CEO to Present at JP Morgan Healthcare Conference and Biotech Showcase - StockTitan
Perspective Therapeutics, Inc. (NYSE:CATX) Shares Sold by Jane Street Group LLC - Defense World
John Finn named CSO of Basecamp - BioCentury
Perspective Therapeutics Appoints New Chief Financial Officer - TipRanks
Perspective Therapeutics Announces Chief Financial Officer Changes - Marketscreener.com
Perspective Therapeutics Names Juan Graham as Finance Chief - MarketWatch
Perspective Therapeutics Appoints Juan Graham, MBA as Chief Financial Officer - The Manila Times
Perspective Therapeutics Appoints FibroGen Veteran Juan Graham as New CFO to Drive Growth Strategy - StockTitan
Perspective Therapeutics Inc (AMEX: CATX) Could Fell Another -684.31% - Stocks Register
Geode Capital Management LLC Has $15.55 Million Position in Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World
Barclays PLC Grows Stock Holdings in Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World
Perspective Therapeutics, Inc. (NYSE:CATX) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Bullish On Perspective Therapeutics: Early Successes And Large Oncology TAM - Seeking Alpha
Perspective Therapeutics, Inc.(NYSEAM:CATX) dropped from S&P Biotechnology Select Industry Index - Marketscreener.com
State Street Corp Grows Position in Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World
Perspective Therapeutics, Inc. (NYSE:CATX) Shares Acquired by State Street Corp - MarketBeat
Minerva Surgical (NASDAQ:UTRS) versus Perspective Therapeutics (NYSE:CATX) Financial Contrast - Defense World
Perspective Therapeutics: Definitely Not Looking Overvalued Now - Seeking Alpha
Pliant Therapeutics Inc (PLRX): A New Perspective - Stocks Register
5.14%
2.09%
Cap:
|
Volume (24h):